BamSEC and AlphaSense Join Forces
Learn More

Passage Bio Inc. – Material Contracts

NASDAQ: PASG    
Share price (9/29/26): $4.63    
Market cap (9/29/26): $14.9 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.36
from S-4/A 70 pages Portions of This Exhibit, Indicated by [***], Have Been Omitted in Accordance With Item 601(b)(10) (IV) of Regulation S-K. the Omitted Information Is (I) Not Material and (II) Treated by the Registrant as Private or Confidential. Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request
12/34/56
EX-10.6
from 8-K 19 pages Form of Contingent Value Rights Agreement Between Passage Bio, Inc. and [•], as Rights Agent Dated as of [•] F-1
12/34/56
EX-10.6
from 425 19 pages Form of Contingent Value Rights Agreement Between Passage Bio, Inc. and [•], as Rights Agent Dated as of [•] F-1
12/34/56
EX-10.5
from 425 16 pages Form of Registration Rights Agreement
12/34/56
EX-10.5
from 8-K 16 pages Form of Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 24 pages Amended and Restated Subscription Agreement
12/34/56
EX-10.4
from 425 24 pages Amended and Restated Subscription Agreement
12/34/56
EX-10.3
from 8-K 13 pages Lock-Up Agreement
12/34/56
EX-10.39
from S-4/A 16 pages Portions of This Exhibit, Indicated by [***], Have Been Omitted in Accordance With Item 601(b)(10) (IV) of Regulation S-K. the Omitted Information Is (I) Not Material and (II) Treated by the Registrant as Private or Confidential. Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request. Master Services Agreement
12/34/56
EX-10.3
from 425 13 pages Lock-Up Agreement
12/34/56
EX-10.2
from 425 13 pages Remix Therapeutics, Inc. Support Agreement
12/34/56
EX-10.38
from S-4/A 17 pages Portions of This Exhibit, Indicated by [***], Have Been Omitted in Accordance With Item 601(b)(10) (IV) of Regulation S-K. the Omitted Information Is (I) Not Material and (II) Treated by the Registrant as Private or Confidential. Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request. Master Services Agreement
12/34/56
EX-10.2
from 8-K 13 pages Remix Therapeutics, Inc. Support Agreement
12/34/56
EX-10.37
from S-4/A 19 pages Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request. Master Services Agreement
12/34/56
EX-10.1
from 8-K 10 pages Passage Bio, Inc. Support Agreement
12/34/56
EX-10.1
from 425 10 pages Passage Bio, Inc. Support Agreement
12/34/56
EX-10.36
from S-4/A 70 pages Portions of This Exhibit, Indicated by [***], Have Been Omitted in Accordance With Item 601(b)(10) (IV) of Regulation S-K. the Omitted Information Is (I) Not Material and (II) Treated by the Registrant as Private or Confidential. Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request
12/34/56
EX-10.35
from S-4 15 pages Portions of This Exhibit, Indicated by [***], Have Been Omitted in Accordance With Item 601(b)(10) (IV) of Regulation S-K. the Omitted Information Is (I) Not Material and (II) Treated by the Registrant as Private or Confidential. Portions of This Exhibit Have Been Omitted in Accordance With Item 601(a)(5) of Regulation S-K. the Registrant Undertakes to Furnish a Copy of All Omitted Information, Schedules, and Exhibits to the U.S. Securities and Exchange Commission Upon Its Request
12/34/56
EX-10.34
from S-4 5 pages Remix Therapeutics, Inc. 400 Technology Square Cambridge, Ma 02139 August 3rd, 2020
12/34/56
EX-10.33
from S-4 8 pages Remix Therapeutics Inc. Aug 1, 2019
12/34/56